Literature DB >> 28007011

Mimicking the Acute Myeloid Leukemia Niche for Molecular Study and Drug Screening.

Mohammad Houshmand1, Masoud Soleimani2, Amir Atashi3, Giuseppe Saglio4, Mohammad Abdollahi2, Mahin Nikougoftar Zarif1.   

Abstract

Bone marrow niche is a major contributing factor in leukemia development and drug resistance in acute myeloid leukemia (AML) patients. Although mimicking leukemic bone marrow niche relies on two-dimensional (2D) culture conditions, it cannot recapitulate complex bone marrow structure that causes introduction of different three-dimensional (3D) scaffolds. Simultaneously, microfluidic platform by perfusing medium culture mimic interstitial fluid flow, along with 3D scaffold would help for mimicking bone marrow microenvironment. In this study TF-1 cells were cocultured with bone marrow mesenchymal stem cells (BM-MSCs) in 2D and 3D microfluidic devices. Phenotype maintenance during cell culture and proliferation rate was assayed and confirmed by cell cycle analysis. Morphology of cells in 2D and 3D culture conditions was demonstrated by scanning electron microscopy. After these experiments, drug screening was performed by applying azacitidine and cytarabine and cytotoxicity assay and quantitative reverse transcription-polymerase chain reaction (qRT-PCR) for B cell lymphoma 2 (BCL2) were done to compare drug resistance in 2D and 3D culture conditions. Our result shows leukemic cells in 3D microfluidic device retaining their phenotype and proliferation rate was significantly higher in 3D culture condition in comparison to 2D culture condition (p < 0.05), which was confirmed by cell cycle analysis. Cytotoxicity assay also illustrated drug resistance in 3D culture condition and qRT-PCR demonstrated higher BCL2 expression in 3D microfluidic device in contrast to 2D microfluidic device (p < 0.05). On balance, mimicking bone marrow niche would help the target therapy and specify the role of niche in development of leukemia in AML patients.

Entities:  

Keywords:  CFSE; bone marrow niche; drug resistance; leukemia; mesenchymal stem cells; microfluidics

Mesh:

Substances:

Year:  2017        PMID: 28007011     DOI: 10.1089/ten.TEC.2016.0404

Source DB:  PubMed          Journal:  Tissue Eng Part C Methods        ISSN: 1937-3384            Impact factor:   3.056


  11 in total

Review 1.  Drug discovery and therapeutic delivery for the treatment of B and T cell tumors.

Authors:  Regan Stephenson; Ankur Singh
Journal:  Adv Drug Deliv Rev       Date:  2017-06-15       Impact factor: 15.470

Review 2.  Tissue engineered models of healthy and malignant human bone marrow.

Authors:  Alan Chramiec; Gordana Vunjak-Novakovic
Journal:  Adv Drug Deliv Rev       Date:  2019-04-17       Impact factor: 15.470

3.  Modelling acute myeloid leukemia (AML): What's new? A transition from the classical to the modern.

Authors:  Annachiara Dozzo; Aoife Galvin; Jae-Won Shin; Santo Scalia; Caitriona M O'Driscoll; Katie B Ryan
Journal:  Drug Deliv Transl Res       Date:  2022-08-05       Impact factor: 5.671

Review 4.  In Vitro and In Vivo Modeling of Normal and Leukemic Bone Marrow Niches: Cellular Senescence Contribution to Leukemia Induction and Progression.

Authors:  Myriam Janeth Salazar-Terreros; Jean-Paul Vernot
Journal:  Int J Mol Sci       Date:  2022-07-01       Impact factor: 6.208

5.  Microphysiological Systems: Next Generation Systems for Assessing Toxicity and Therapeutic Effects of Nanomaterials.

Authors:  Nureddin Ashammakhi; Mohammad Ali Darabi; Betül Çelebi-Saltik; Rumeysa Tutar; Martin C Hartel; Junmin Lee; Saber Hussein; Marcus J Goudie; Mercedes Brianna Cornelius; Mehmet R Dokmeci; Ali Khademhosseini
Journal:  Small Methods       Date:  2019-11-11

6.  Culturing patient-derived malignant hematopoietic stem cells in engineered and fully humanized 3D niches.

Authors:  Andrés García-García; Thibaut Klein; Gordian Born; Morgane Hilpert; Arnaud Scherberich; Claudia Lengerke; Radek C Skoda; Paul E Bourgine; Ivan Martin
Journal:  Proc Natl Acad Sci U S A       Date:  2021-10-05       Impact factor: 11.205

Review 7.  Chronic myeloid leukemia stem cells.

Authors:  Mohammad Houshmand; Giorgia Simonetti; Paola Circosta; Valentina Gaidano; Alessandro Cignetti; Giovanni Martinelli; Giuseppe Saglio; Robert Peter Gale
Journal:  Leukemia       Date:  2019-05-24       Impact factor: 11.528

Review 8.  Moving Myeloid Leukemia Drug Discovery Into the Third Dimension.

Authors:  Donna M Cartledge Wolf; Sigrid A Langhans
Journal:  Front Pediatr       Date:  2019-07-30       Impact factor: 3.418

Review 9.  Halfway between 2D and Animal Models: Are 3D Cultures the Ideal Tool to Study Cancer-Microenvironment Interactions?

Authors:  Jessica Hoarau-Véchot; Arash Rafii; Cyril Touboul; Jennifer Pasquier
Journal:  Int J Mol Sci       Date:  2018-01-18       Impact factor: 5.923

10.  MicroRNA Microarray Profiling during Megakaryocyte Differentiation of Cord Blood CD133+ Hematopoietic Stem Cells.

Authors:  Mohammad Houshmand; Mozhde Nakhlestani Hagh; Masoud Soleimani; Amir Ali Hamidieh; Saeed Abroun; Mahin Nikougoftar Zarif
Journal:  Cell J       Date:  2018-03-18       Impact factor: 2.479

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.